See the DrugPatentWatch profile for ruxolitinib

Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was officially approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain blood disorders on November 16, 2011 [1]. However, the specific approval of Ruxolitinib by Apotex, a Canadian-based pharmaceutical company, is not explicitly mentioned in the FDA's drug approval database [2]. It is important to note that the FDA's approval process is for the drug itself, not for a specific manufacturer. Once a drug is approved, other manufacturers can produce and market it as a generic version, provided they meet certain requirements.

Therefore, while Ruxolitinib as a drug was approved by the FDA in 2011, the specific approval date for Apotex as a manufacturer is not publicly available.

Sources:
[1] U.S. Food and Drug Administration. (2011). FDA approves new drug to treat certain blood disorders.
<https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-certain-blood-disorders>
[2] DrugPatentWatch. (n.d.). Ruxolitinib.
<https://www.drugpatentwatch.com/drugs/ruxolitinib>